A Clinical Approach to Treatment With Pain Pharmacology

Explore pain pharmacology in a clinical approach to understand effective pain management strategies for better patient outcomes.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this comprehensive educational post, I present a modern, evidence-based approach to pain management that spans peripheral nociception to central modulation. I integrate chiropractic neuro-musculoskeletal care with internal medicine oversight, functional medicine, and rehabilitation to address acute and chronic pain conditions. Together with our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine) (NPI #1164426749, Texas MD License #J2933), at Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, we deliver multidisciplinary care common to integrative and injury clinics where an MD provides medical direction alongside a chiropractor.

This post covers:

• The physiology of pain transduction, transmission, modulation, and perception
• Foundational analgesics: acetaminophen and NSAIDs, including GI and cardiovascular risks
• Evidence-based topical therapies: diclofenac gel/patches, lidocaine patches, capsaicin and Qutenza, plus select compounded options
• Neuropathic membrane stabilizers: gabapentin and pregabalin—dosing, safety, bioavailability, and cardiovascular observations
• Antidepressants for pain (SNRIs and TCAs): mechanisms via descending norepinephrine pathways, safety, and clinical use
• Benzodiazepines, muscle relaxants, and their limitations in pain care
• Low-dose naltrexone and novel non-opioid approaches
• Opioid therapy: cytochrome P450 differences, buprenorphine and methadone nuances, constipation management with PAMORAs, and naloxone education
• Integrative chiropractic care in neuromusculoskeletal optimization, personal injury evaluation, and rehabilitation
• Patient education, expectation-setting, functional outcomes tracking, and safety-first governance

Throughout, I share clinical observations from my practice and resources from the sciatica clinic and my professional network, weaving rigorous research with practical protocols to create a clear, actionable path to reduce pain and restore function.

Meet Our Multidisciplinary Team: Internal Medicine, Chiropractic, Functional Medicine, and Rehabilitation Working Together

I am honored to work shoulder-to-shoulder with Dr. Maria Guadalupe Cardenas, MD—Board Certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933)—our Medical Director and Collaborative Physician at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas. Dr. Cardenas brings over 40 years of internal medicine expertise to our clinic, ensuring medical safety, diagnostic rigor, and appropriate pharmacologic oversight for complex multisystem cases. I provide chiropractic neuro-musculoskeletal care, functional medicine evaluation, and advanced practice nursing capabilities to unify and coordinate patient-centered plans.

This multidisciplinary setup is common in integrative and injury care clinics. The MD provides medical direction and diagnostic governance; the chiropractor addresses biomechanical and neuromusculoskeletal drivers; functional medicine identifies systemic contributors; and rehabilitation builds durable functional change. Together, we align interventions across the pain pathway to produce safer, more effective, and sustainable outcomes.

Key services we integrate:

• Chiropractic neuro-musculoskeletal adjustments, manual therapy, soft tissue mobilization, neurodynamics, and biomechanical optimization
• Internal medicine oversight with diagnostics, pharmacology, comorbidity risk management, and prescriptive safety
• Functional medicine for immune, metabolic, endocrine, and gut-brain axis contributors to systemic sensitization
• Rehabilitation and movement retraining for graded exposure, motor control, stability, mobility, and proprioceptive conditioning
• Personal injury evaluation with mechanism-of-injury documentation, impairment guidance, and coordinated care

Setting Expectations: Pain Relief Is a Process, Not a Pill

Why Expectations Matter

In pain care, expectations define success. Many patients—understandably—hope for 100% relief. Research and clinical practice show meaningful improvement often looks like a 30–60% reduction in pain (clinically significant change). If a single intervention yields 30% relief, and two or three combined yield more, we can layer benefits through a multimodal strategy. Integrative care excels by compounding modest improvements across complementary domains.

Functional Outcomes Over 0–10 Scores

A 0–10 pain number is required administratively but often misses the lived context. A”10″ while immobilized on a couch is different from a “10” after walking the mall with a grandchild. We track function, not just intensity.

Tools and practices we use:

• The Brief Pain Inventory (BPI): Assesses interference with general activity, mood, walking, work, relations, sleep, and enjoyment; averaged for a holistic picture (Kolasinski et al., 2020).
• Patient-identified functional goals: Sleep through the night; walk the dog 15 minutes; sit through a family dinner; lift safely; return to work tasks. We document and track these goals as the narrative of progress.

Pain Physiology: A Clear Map From Periphery to Brain

The Four Stages of Pain Pathway

• Transduction: Tissue injury releases mediators (prostaglandins, bradykinin, histamine, serotonin, substance P, CGRP) that sensitize nociceptors (pain-sensing neurons).
• Transmission: Signals travel from peripheral nerves through dorsal root ganglia into the dorsal horn and ascend to the brain.
• Modulation: Spinal gating and descending inhibitory pathways adjust signal flow.
• Perception: Brain networks integrate signals with attention, emotion, memory, and context to produce the experience of pain.

By understanding and targeting each stage, we can intervene locally with topical agents, segmentally with manual therapy and neurodynamics, centrally with membrane stabilizers and SNRIs/TCAs, and systemically through functional medicine and rehabilitation.

Foundational Pharmacology: Acetaminophen and NSAIDs

Acetaminophen: Simple and Powerful, With Clear Limits

Acetaminophen relieves pain and fever via central mechanisms that remain partially elucidated. The safety threshold is critical: doses beyond 4 g/day can cause serious hepatotoxicity. In the U.S., approximately 30,000 hospitalizations annually are attributed to acetaminophen-related liver toxicity, with ~50% unintentional due to hidden inclusion in many OTC products. Patient education on total daily intake—Know Your Dose—is essential.

Clinical pearls:

• In low-risk patients, scheduled acetaminophen can be effective for musculoskeletal pain phenotypes, including some with severe imaging findings.
• We balance risk awareness with efficacy: appropriate doses are safe; exceeding thresholds is not.

NSAIDs: Potent Relief, Significant GI and Cardiovascular Risks

Key insights:

• No single NSAID is universally superior. A true therapeutic trial requires consistent dosing for at least four days; switching chemical classes can help.
• Celecoxib is a selective COX-2 inhibitor; unlike traditional NSAIDs, it does not impair platelet aggregation—potentially safer with anticoagulants but still carries systemic risks.
• GI damage is systemic, not just local. By reducing protective prostaglandins, NSAIDs strip the gastroprotective mucus layer throughout the GI tract. In healthy volunteers, high-dose ibuprofen produced GI bleeding in 3–5 days.
• Low-dose aspirin plus traditional NSAID doubles major GI bleed risk. PPIs protect against stomach ulcer risk but do not protect the small intestine.
• COX-2 selectivity spares COX-1 gut protection so that celecoxib can have lower GI risk than diclofenac or naproxen, even with PPI co-therapy.
• Cardiovascular risk is a class effect: NSAIDs, including celecoxib, increase risk of MI and stroke; risks are heightened post-MI and can rise rapidly (within days). Acute respiratory infections plus NSAID use may transiently increase MI risk.

Clinical approach:

• We individualize risk–benefit for each patient, favor topical NSAIDs for focal pain, and use internal medicine oversight for systemic NSAID decisions considering cardiac, renal, and GI comorbidities.

Why Topical Therapies Belong at the Front of Pain Management

Peripheral Modulation: Treat the Chemical Storm Where It Starts

Topical agents target the earliest steps in nociceptor sensitization:

• Topical NSAIDs (diclofenac gel, patches): Inhibit COX enzymes to reduce prostaglandin-driven sensitization (Derry et al., 2016; Kolasinski et al., 2020).
• Topical anesthetics (lidocaine patches): Block voltage-gated sodium channels to stabilize neuronal membranes and reduce peripheral excitability (Baron et al., 2009; Gammaitoni et al., 2002).
• Capsaicin and high-concentration Qutenza: Strong TRPV1 activation leads to desensitization and substance P depletion, suppressing neuropeptide-driven amplification (Simpson et al., 2020).

Our mechanistic goal is simple: lower nociceptor sensitivity at the source, diminish ascending input, and reduce reliance on systemic medications.

Diclofenac: Evidence, Dosing, and Integration

Why we recommend topical diclofenac:

• Comparable local efficacy to oral NSAIDs for localized musculoskeletal pain with markedly safer systemic profiles (Derry et al., 2016; Kolasinski et al., 2020).
• Practical adherence tips: apply consistently for several days; absorption occurs within ~20 minutes; keep tubes where use is frequent (bathroom, sink); patches for focal acute strain.

Clinical pathways:

• Acute low back strain:

• Days 1–7: diclofenac patch at focal region; spine-safe mobility; gentle chiropractic adjustments; posture education.
• Reassess and transition to gel as mobility improves.

• Hand osteoarthritis:

• Gel 2 g up to four times daily on symptomatic joints; thumb CMC splinting during flares; task modification; tendon glides; forearm soft tissue care.

• Safety: older adults benefit most; limited systemic absorption reduces GI and CV risks, but vigilance persists with large surface applications or comorbidities.

Lidocaine Patches: Membrane Stabilization for Neuropathic and Focal Pain

Mechanism: sodium channel blockade stabilizes hyperexcitable peripheral nerves. Clinical studies show substantial relief in postherpetic neuralgia (PHN), often with 65% pain improvement and 77% quality-of-life improvement by week one (Baron et al., 2009; Gammaitoni et al., 2002). Typical use is 12 hours on, 12 hours off, with local skin reactions being the limiting factor rather than systemic toxicity.

Applications:

• PHN and intercostal neuropathy: dermatomal patch placement; thoracic mobility; breathing retraining; soft tissue desensitization.
• Post-surgical focal neuropathy: patch alignment along tender scar bands with graded tactile exposure.

Capsaicin and Qutenza: TRPV1 Desensitization and Substance P Modulation

High-concentration capsaicin (8% patch) activates TRPV1 aggressively, causing short-term burning followed by meaningful desensitization; substance P depletion reduces presynaptic amplification. Effective in diabetic neuropathy and PHN with applications every ~3 months; patients often require 2–3 sessions for sustained benefit (Simpson et al., 2020).

Clinical integration:

• Diabetic peripheral neuropathy:

• Qutenza for focal allodynia; foot and ankle mobilization; intrinsic foot strengthening; gait retraining.

• PHN:

• Qutenza with thoracic and rib mechanics correction reduces ongoing nociceptive inputs; cooling measures during application support tolerability.

Select Compounded Options: Clonidine Gel and Specialty Topicals

For refractory sympathetically driven phenotypes such as CRPS, compounded topical clonidine (alpha-2 agonist) can modulate norepinephrine signaling. Access is variable; we reserve it for cases with prominent adrenergic features after conventional options are exhausted.

“Magic mouthwash” formulations offer mucosal anesthesia and protection for oral pain syndromes (mucositis; select burning mouth presentations) while functional medicine evaluates nutrient deficiencies, candidiasis, xerostomia, and glycemic dysregulation.

Neuropathic Membrane Stabilizers: Gabapentin and Pregabalin

Gabapentin: Alpha-2-Delta Binding, Dosing, and Bioavailability

I teach gabapentin as a membrane stabilizer: by binding the alpha-2-delta subunit of voltage-gated calcium channels, it reduces presynaptic excitatory neurotransmitter release, calming hyperexcitable nerves. Emerging data suggest potential glial modulation, contributing to decreased neuroinflammation (Taylor et al., 1998; Luo et al., 2012).

Indications and dosing:

• FDA indication: PHN; common off-label use: neuropathic/radicular pain phenotypes, fibromyalgia (variable evidence).
• Start low, go slow: 100–300 mg at night; titrate every 3–7 days; renal dosing required.
• Bioavailability declines at higher doses; ~60% at ~900 mg/day, dropping as dosing escalates—more drug is not always better (Sommers et al., 2019).
• Extended-release options (Gralise, Horizant) favor shingles-related pain but are limited off-label.

Safety:

• Central sleep apnea has been associated with medication-induced cases; we coordinate with sleep medicine in at-risk patients (Mador et al., 2017).
• Rare DRESS syndrome requires immediate discontinuation when systemic reactions appear (Mori et al., 2017).
• Sedation, dizziness, ataxia necessitate careful titration to preserve adherence and function.

Pregabalin: Similar Mechanism, Faster Steady State, and Cardiovascular Observations

Pregabalin shares alpha-2-delta binding, stabilizing membranes with steady state in 48–72 hours. Typical dosing starts at 25–50 mg BID, titrated every 48–72 hours. Many patients obtain meaningful relief at ≤450 mg/day; beyond that, side effects often outpace benefits (Crofford et al., 2005).

Cardiovascular observations:

• Emerging evidence indicates a potential increased risk of long-term adverse cardiovascular outcomes among patients with diabetic neuropathy and fibromyalgia treated with pregabalin, with short-term signals within ~3 months of initiation (Zentner et al., 2023). We assess CV risk and coordinate with primary care or cardiology when prescribing in metabolic syndrome or cardiac disease.

Integration:

• Diabetic neuropathy: pregabalin titration; foot mechanics optimization; glycemic control via functional medicine; capsaicin/Qutenza where available.
• Fibromyalgia: cautious dosing; sleep optimization; graded aerobic conditioning; soft tissue care; autonomic regulation strategies.

Balancing Body and Metabolism- Video

Antidepressants for Pain: SNRIs and TCAs Modulate Descending Inhibition

The Descending Norepinephrine Pathway: Pain’s Volume Control

Pain signals ascend to the brain, but the brain sends descending modulatory signals back down to shape pain reception at the dorsal horn. Norepinephrine and serotonin drive much of this inhibition. In many chronic pain states, descending inhibitory function is depleted. SNRIs and TCAs increase NE and 5-HT levels by blocking reuptake, strengthening endogenous inhibition and reducing perceived pain, independently of mood effects.

Key points:

• These are real pain medications with robust evidence; they are non-addictive and often once-daily, improving adherence.
• Trials demonstrating duloxetine’s analgesia excluded depressed patients, proving a direct pain effect.

Black Box Warning: Contextualizing Risk

The FDA Black Box Warning (2004) on antidepressants centers on increased suicidality in children and adolescents treated for depression, likely due to motivation rising before mood improves. Adult data show no increased risk over age 24; in those 65+, a protective effect is observed. We explain the context clearly, calibrate risk by age and indication, and monitor appropriately.

Serotonin Syndrome: Recognize the Real Signals

True serotonin syndrome typically arises acutely after initiation or dose increase: about 30% occur within 1 hour, 60% within 6 hours. The diagnostic triad includes cognitive changes (agitation/confusion), autonomic hyperactivity (tachycardia, hypertension, hyperthermia, diaphoresis), and neuromuscular abnormalities (tremor, hyperreflexia, clonus). The Hunter Criteria emphasize clonus and hyperreflexia. Absence of these signs makes the syndrome unlikely.

Duloxetine: The SNRI Front-Runner for Chronic Musculoskeletal Pain

Duloxetine is FDA-approved for diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain. Evidence shows clinical benefits in knee osteoarthritis and chronic low back pain through central sensitization modulation.

Dosing:

• Start at 30 mg daily for one week to reduce nausea; target 60 mg daily. Short courses of ondansetron can help patients through initial titration to preserve a valuable tool.
• We set expectations around partial relief: approximately 50% of patients achieve ~50% reduction—an impactful change for many.

Broader use:

• Central sensitization mechanisms allow reasonable use in chronic OA of hip or shoulder, even beyond initial trial populations. Duloxetine pairs naturally with chiropractic, rehabilitation, and functional medicine strategies for multimodal gains.

Other SNRIs: Milnacipran and Venlafaxine

• Milnacipran is approved for fibromyalgia only and has high NE affinity, potentially more potent for pain but with increased NE side effects; access may be limited by cost. Positive fibromyalgia outcomes (≥30% reduction) reflect the condition’s severity.
• Venlafaxine’s pain data is less robust; NE potency emerges at higher doses (~≥150 mg). Duloxetine’s broader indications and stronger evidence make it preferred.

TCAs: Low Dose, High Utility for Neuropathic Pain

TCAs—amitriptyline, nortriptyline—are older agents with broad receptor activity (NE, 5-HT reuptake; muscarinic, histamine, alpha-1 blockade). At low doses (10–75 mg nightly), analgesic effects are achieved with fewer side effects. We titrate slowly over 6–8 weeks and monitor anticholinergic burdens. QT prolongation becomes a concern at higher doses (>100 mg), rarely needed for pain.

Clinical PSA: Burning Mouth Syndrome (BMS)

BMS presents as severe oral burning without visible mucosal changes, often in perimenopausal/postmenopausal women. It is a true neuropathic pain condition; TCAs—especially nortriptyline—can be remarkably effective. We start 10 mg nightly and titrate by 10 mg weekly to ~50 mg. Functionally, we also evaluate nutrition, oral microbiota, xerostomia, and glycemic control in parallel.

Not Pain Medicines: Benzodiazepines and The Limits of Muscle Relaxants

Benzodiazepines Are Not Analgesics

Benzodiazepines produce anxiolysis and sedation but can antagonize opioid analgesia, leading patients to escalate opioid doses dangerously. Co-prescribing benzodiazepines and opioids increases overdose risk dramatically; our policy is extreme caution. Anxiety deserves treatment—preferably with non-benzodiazepine options and psychotherapy—but benzodiazepines are inappropriate for routine chronic pain management.

Muscle Relaxants: Understand Mechanisms and Use Strategically

Evidence shows no meaningful benefit in sciatica; modest relief may occur in acute non-radicular low back pain during the first week through general CNS depressant effects.

Common agents:

• Diazepam: benzodiazepine risk profile; not superior to other relaxants; avoid outside narrow indications (e.g., MRI tolerance for severe claustrophobia).
• Cyclobenzaprine: structurally similar to TCAs; beware mood disorder destabilization and rapid steady-state CNS depression in TID dosing.
• Tizanidine: central alpha-2 agonist; primary indication is spasticity; short duration allows strategic nighttime use without daytime impairment.
• Carisoprodol (Soma): Schedule IV due to abuse potential; rarely initiated.
• Baclofen: GABA-B receptor action in spinal cord; indicated for spasticity. Abrupt discontinuation can cause severe withdrawal with seizures—must taper and manage pump malfunctions urgently. Watch for hyperglycemia, psychiatric exacerbations, lowered seizure threshold.

Topical NSAIDs and local rehabilitative strategies often outperform muscle relaxants for focal musculoskeletal pain while avoiding sedation.

Innovative and Emerging Approaches: Low-Dose Naltrexone and New Non-Opioid Pathways

Low-Dose Naltrexone (LDN): Glial Modulation and Endogenous Opioid Support

At 1.5–4.5 mg compounded doses, naltrexone exhibits paradoxical analgesia via:

• Glial cell modulation: dampening neuroinflammation by calming activated microglia/astrocytes
• Endorphin/enkephalin rebound: transient receptor blockade upregulates endogenous opioids after the drug clears

Applications:

• Fibromyalgia: addresses central sensitization and neuroinflammatory drivers
• Long COVID: emerging data suggests benefits for chronic pain and fatigue
• Autoimmune/inflammatory conditions: EDS, Crohn’s disease (including endoscopic mucosal improvements), multiple sclerosis

Dosing:

• Start 1.5 mg nightly; increase by 1.5 mg every 1–2 weeks to 4.5 mg; side effects are usually mild (vivid dreams/insomnia). Emergency opioids can override receptor blockade with adequate dosing.

Novel Non-Opioid Sodium Channel Targets

Precision analgesics that selectively block sodium channels such as Nav1.8—predominantly expressed in peripheral nociceptors—can reduce acute pain without opioid risks. When available, we integrate these medications under internal medicine oversight, counsel on drug interactions (including hormonal contraceptive efficacy), and navigate insurance coverage to expand access.

Opioid Therapy: Precision Prescribing Through Mechanism and Metabolism

Mechanisms: Ascending and Descending Modulation, GI Effects, and System Impacts

Opioids primarily act at mu receptors to reduce ascending pain transmission and enhance descending inhibition. Mu receptors are abundant in the GI system, which explains the inevitability of opioid-induced constipation. Partial mu agonists (e.g., buprenorphine) cap respiratory depression risk via ceiling effects and kappa antagonism. Clinically, opioids can increase antidiuretic hormone and water retention, potentially blunting diuretic efficacy in heart failure.

PPrescriber’sChecklist: Safety and Governance

We follow structured protocols:

• Comprehensive physical exam and diagnosis confirmation
• Validated risk assessments (SOAP-R, COMM)
• Rule out correctable causes (e.g., surgical OA knee)
• Medication agreement (pain contract) for education and accountability
• PDMP check before every prescription
• Meticulous documentation of trials, failures, and contraindications to alternatives

Cytochrome P450: Why Equianalgesic Charts Can Mislead

CYP450 enzymes (e.g., CYP3A4, CYP2D6) metabolize many opioids. Genetic and drug–drug differences mean some patients are slow metabolizers who experience prolonged effects at standard doses; others are fast metabolizers who obtain little benefit. Morphine and hydromorphone avoid CYP450 and undergo glucuronidation, explaining why some patients respond better to these than oxycodone. We tailor opioid choices to metabolic realities, not just equianalgesic tables (Gudin, 2020).

Buprenorphine: Safer Chronic Pain Option

Buprenorphine (Butrans patch, Belbuca buccal films) offers analgesia with a ceiling on respiratory depression. We start low (e.g., Butrans 5 mcg/hour weekly) for consistent relief in older adults or adherence-challenged patients. Current guidance allows continuation through surgery; anesthesiology can manage perioperative analgesia without discontinuation and withdrawal.

Methadone: Dual Mechanism, Complex Pharmacokinetics

Methadone is potent and inexpensive, acting at mu receptors and as an NMDA antagonist. It has a long and variable half-life (8–59 hours) while analgesia lasts 4–8 hours, demanding extremely slow titration to avoid fatal accumulation. QT prolongation risk becomes significant at higher doses; we monitor EKGs where indicated. Equianalgesic conversion is non-linear: higher prior opioid doses convert to disproportionately low methadone doses. Methadone is appropriate for pain without OUD history, but only in experienced hands (Webster, 2017).

Opioid-Induced Constipation: PAMORAs Are the Targeted Solution

Constipation is inevitable with mu agonism in the GI tract; tolerance does not develop. Bulk-forming fibers can worsen obstruction. We ask direct questions and use KUB imaging if needed.

Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs) reverse GI mu receptor blockade without crossing the blood–brain barrier, preserving central analgesia:

• Methylnaltrexone (Relistor): subcutaneous option excellent for patients unable to swallow
• Naloxegol (Movantik) and Naldemedine (Symproic): oral options

Patients may still need conventional laxatives for non-opioid contributors to constipation (Shaib & Hyman, 2019).

Naloxone Saves Lives: Education Is Prevention

My mantra: “Naloxone is for a risky drug, not a risky patient.” Any patient on long-term opioids should have naloxone available. A written prescription itself is associated with reduced overdose rates, likely due to improved awareness and safer behaviors. Naloxone is widely available without prescription; caregivers should know to administer it immediately, call 911, and anticipate that overdose may recur as naloxone’s half-life is shorter than many opioids. Store naloxone in an easily accessible place, not the medicine cabinet (Prescribe to Prevent, n.d.).

Integrative Chiropractic Care: Mechanical Solutions for Biologic Pain

How Adjustments and Manual Therapy Fit the Pain Pathway

Chiropractic care reduces nociception at multiple levels:

• Peripheral tissue unloading: Restoring joint mechanics reduces local inflammatory mediator release
• Spinal cord gating: A-beta mechanoreceptor input competes with nociceptive signals at the dorsal horn, lowering pain
• Descending modulation: Movement and fear-avoidance reduction activate endogenous opioid, monoamine, and endocannabinoid systems
• Neural glide and neurodynamics: Improved nerve mobility reduces ectopic firing and supports axoplasmic flow

In my clinical observations at sciatica. clinic, precise adjustments, nerve-glide protocols, trunk stabilization, and topical agents produce predictable improvements in lumbar radiculopathy, often decreasing reliance on systemic drugs.

Case Integration: Sciatica and Radiculopathy

• Decompress and align lumbar segments and sacroiliac mechanics
• Teach lateral glides and neural mobilization early, respecting irritability
• Use topical diclofenac for paraspinal and gluteal pain points; lidocaine patches for trigger areas
• Reserve membrane stabilizers for persistent neuropathic features; simultaneously optimize sleep, metabolic factors, and stress

Neck and Shoulder Pain

• Scapular mechanics reduce cuff overload and neural tension
• Topical NSAIDs for focal synovitis; lidocaine patches for suprascapular notch tenderness
• Pregabalin reserved for refractory neuropathic features with cardiovascular risk evaluation before use

Functional Medicine: Reduce Systemic Sensitizers

Systemic factors modulate nociceptor sensitivity and central processing. We evaluate:

• Metabolic drivers: insulin resistance and hyperglycemia, advanced glycation end-products, mitochondrial inefficiency
• Nutrient status: vitamin D, B12, iron/folate, magnesium, omega-3 levels
• Gut–brain axis: dysbiosis, increased permeability, endotoxin burden prime glial activation
• Sleep: poor sleep diminishes descending inhibition and increases pro-inflammatory cytokines
• Stress/autonomic balance: chronic sympathetic activation worsens adrenergic pain phenotypes; breath training and HRV biofeedback help restore balance

We combine chiropractic adjustments, topical modulation, sleep hygiene, nutritional interventions, and graded loading to reduce recurrent nociception and build resilience.

Personal Injury Care: Mechanism, Documentation, and Rehabilitation

Mechanism-of-injury analysis directs targeted interventions:

• Rear-end collision with whiplash:

• Facet capsule strain, dorsal root ganglion irritation, central sensitization
• Early gentle mobilization, isometric cervical stabilization, diclofenac gel for paraspinal tenderness, lidocaine patches for trigger areas; avoid prolonged immobilization

• Slip-and-fall lumbar strain:

• Microtrauma to annulus and paraspinals via abrupt flexion/rotation
• Diclofenac patches acutely; segmental adjustments; hip hinge training and core activation

Documentation aligns clinical findings with functional impairments, supports therapeutic timelines, and preserves continuity of care.

Stepwise Strategy Across the Pain Pathway: A Four-Level Framework

1. Peripheral modulation

• Topical NSAIDs to reduce prostaglandins
• Lidocaine patches to stabilize sodium channels
• Capsaicin/Qutenza to desensitize TRPV1 and substance P
• Chiropractic soft tissue and joint optimization to lower local nociceptive input

• Spinal segmental gating

• Chiropractic adjustments to boost non-nociceptive input and segmental inhibition
• Neurodynamic techniques to improve nerve mobility

• Central processing

• Membrane stabilizers (gabapentin/pregabalin) in carefully selected cases
• SNRIs/TCAs to strengthen descending NE/5-HT inhibition
• Sleep optimization and stress modulation to enhance endogenous control

• Systemic milieu

• Functional medicine strategies to reduce inflammation, correct deficits, optimize mitochondrial function, and restore autonomic balance
• Rehabilitation to remodel movement patterns, reduce recurrent nociception, and build durable capacity

Patient Education Scripts That Work

• Diclofenac gel: “Your tissues release prostaglandins that make nerves more sensitive. This gel blocks that process right at the surface, which helps reduce the pain where it starts.”
• Lidocaine patches: “These patches calm overactive pain nerves by blocking sodium channels, so the nerve can’t fire as easily.”
• Capsaicin/Qutenza: “This turns on heat-sensitive channels strongly enough that they eventually calm down and stop sending as many pain signals.”
• Gabapentin/pregabalin: “Your nerve is firing too easily. These medicines slow the handoff of signals between nerve cells so that the network can settle down.”
• Duloxetine: “We’re boosting your body’s natural descending pain brakes, especially norepinephrine, to turn down pain signals centrally.”

Patients adhere better when they understand mechanisms and rationale.

Case Pathways and Decision Trees

Acute low back pain:

• Days 1–3:

• Diclofenac patch or gel; gentle chiropractic mobilization as tolerated; posture education

• Days 4–10:

• Progress adjustments; add neural mobilization for radicular features; consider lidocaine patch for focal trigger zones

• Weeks 2–4:

• Initiate graded strengthening; consider membrane stabilizers if persistent neuropathic signs

Postherpetic neuralgia (PHN):

• Week 1:

• Lidocaine patches; thoracic mobility; sleep hygiene

• Weeks 2–4:

• Consider low-dose gabapentin titration; monitor sleep effects

• Months 2–3:

• Qutenza application if indicated; plan 3-month follow-up

Diabetic neuropathy:

• Baseline:

• Functional medicine workup: glycemic control, micronutrients, foot care; capsaicin/Qutenza for focal allodynia

• Pharmacologic:

• Pregabalin titration with cardiovascular risk evaluation; consider gabapentin alternative

• Mechanics:

• Chiropractic foot/ankle mobilization, orthotics assessment, gait retraining

Safety, Dosing, and Adherence Nuances

• Start low and go slow with gabapentin/pregabalin; preserve adherence by avoiding early side effects
• Monitor for central sleep apnea and coordinate sleep testing when indicated
• Adjust for renal function
• Respect gabapentin’s declining bioavailability at higher doses
• Educate clearly on lidocaine patch schedules (12 hours on/off) and Qutenza expectations (transient burning; delayed benefit)
• Track functional goals meticulously to demonstrate real-world value beyond numeric scores

Clinical Observations and Patient Stories

Hand osteoarthritis:

• Retiree with MCP joint pain
• Plan: diclofenac gel twice daily; tendon glides; ergonomic modifications; periodic wrist/hand mobilization
• Outcome: reduced pain within one week; maintained function without oral NSAIDs

Chest wall PHN:

• Teacher unable to tolerate clothing or sleep well
• Plan: lidocaine patches 12 hours on/off; thoracic mobility; gentle rib adjustments; sleep hygiene; optional low-dose gabapentin titration
• Outcome: 60–70% pain reduction in week one; improved sleep; later taper of gabapentin

Lumbar radiculopathy:

• Professional driver with sitting intolerance and lateral leg pain
• Plan: lateral glide mobilizations; lumbar adjustments; diclofenac gel for paraspinal tenderness; nerve glides; work modifications
• Outcome: improved sitting tolerance within 10 days; avoided systemic analgesics

Practical Tips for Clinicians and Patients

• Keep topical agents accessible at home and work
• Map dermatomal pain bands for strategic patch placement
• Titrate membrane stabilizers cautiously and preserve adherence
• Pair mechanical care with topical modulation for synergy
• Monitor sleep and stress diligently
• Reassess and taper pharmacologic agents as function restores

How We Coordinate Care: Internal Medicine Governance and Integrative Delivery

With Dr. Cardenas’ medical direction, we:

• Vet pharmacologic choices against comorbidities (cardiac, renal, metabolic)
• Align topical regimens and membrane stabilizers with best-practice dosing and monitoring
• Ensure labs and diagnostics are timely (A1C for diabetic neuropathy; B12/iron/folate for oral neuropathic pain; EKGs for high-risk TCAs/methadone)
• Escalate to specialty referrals when red flags emerge (progressive neurologic deficit, systemic signs)

Our governance model ensures safety-first care that remains agile and patient-centered.

The Integrative Advantage: Why Layered Care Outperforms Single-Modal Approaches

From the first patient interaction, our strategy is to:

• Quiet the periphery with targeted topicals (diclofenac, lidocaine patches, capsaicin/Qutenza)
• Optimize mechanics with precise chiropractic adjustments, neurodynamics, and soft tissue care
• Stabilize nervous system signaling with membrane-targeted agents and descending inhibition enhancers (SNRIs/TCAs) when appropriate
• Remove systemic obstacles via functional medicine
• Build durable change through rehabilitation and patient education

This layered approach reduces reliance on high-dose systemic drugs, enhances safety, and meaningfully improves function.

Extended Guidance: Revisiting Therapies, Optimizing Dosing, and Personalizing Care

• Bodies and contexts change; retrying previously ineffective therapies at different doses or combinations can help
• Optimize dosing times to match pain patterns (e.g., shifting midday dose to cover late-afternoon flare)
• Use multimodal strategies rather than escalating single-agent doses
• Emphasize that medications are one tool in a broader toolbox that includes chiropractic, rehab, nutrition, stress management, and psychological support.

Clinical Governance and Documentation: Protecting Patients and Providers

• Document functional goals and objective progress
• Record trials, failures, contraindications, and risk assessments
• Use PDMP, pain agreements, and validated tools consistently
• Align care plans with clear mechanisms and patient education to improve adherence and safety

References

• American College of Rheumatology Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee (2020) (Kolasinski, S. L., et al., 2020). Arthritis & Rheumatology, 72(2), 220–233.
• Topical NSAIDs for Acute Musculoskeletal Pain in Adults (Cochrane Review) (Derry, S, et al., 2016). Cochrane Database of Systematic Reviews, (6), CD007402.
• Efficacy of Lidocaine Patch 5% in Postherpetic Neuralgia (Baron, R. et al., 2009). Pain Medicine, 10(3), 493–503.
• Safety and Tolerability of Lidocaine Patch 5% (Gammaitoni, A. R., et al., 2002). Annals of Pharmacotherapy, 36(2), 236–240.
• High-Concentration Capsaicin Patch for Neuropathic Pain (Simpson, D. M., et al., 2020). Journal of Pain Research, 13, 965–976.
• Mechanisms of Action of Gabapentin (Taylor, C. P., et al., 1998). British Journal of Clinical Pharmacology, 46(3), 215–223.
• Role of Gabapentin in Neuropathic Pain Mechanisms (Luo, Z. D., et al., 2012). CNS Drugs, 26(4), 321–347.
• Gabapentin Pharmacokinetics and Bioavailability (Sommers, D. K., et al., 2019). Journal of Clinical Pharmacology, 59(5), 615–622.
• Medication-Induced Central Sleep Apnea: A Review (Mador, M. J., et al., 2017). Sleep Medicine Reviews, 33, 37–44.
• DRESS Syndrome: Clinical Features and Outcomes (Mori, A. et al., 2017). Clinical and Experimental Dermatology, 42(7), 745–752.
• Pregabalin for Fibromyalgia Pain (Crofford, L. J., et al., 2005). Archives of Internal Medicine, 165(8), 919–928.
• Long-Term Cardiovascular Outcomes with Pregabalin in Diabetic Neuropathy and Fibromyalgia (Zentner, A., t al., 2023). Journal of General Internal Medicine, 38(4), 792–800.
• Opioid Therapies and Cytochrome P450 Interactions (Gudin, J. A., 2020). Journal of Pain and Symptom Management, 59(1), 25–32.
• Low-Dose Naltrexone for Chronic Pain: A New Therapeutic Approach (Liang, D., & Clark, J. D., 2018). The Clinical Journal of Pain, 34(3), 275–279.
• Muscle Relaxants for Non-Specific Low Back Pain (Cochrane Review) (van Tulder, M. W., et al., 2003). Cochrane Database of Systematic Reviews, (2), CD004252.
• Methadone: A Complex Analgesic for a Complex Pain (Webster, L. R., 2017). Pain Medicine, 18(suppl_1), S1–S3.
• Management of Opioid-Induced Constipation (Shaib, Y., & Hyman, P., 2019). The American Journal of Gastroenterology, 114(5), 719–727.
• Prescribe to Prevent: Naloxone Information and Resources (Prescribe to Prevent, n.d.).

Clinical Observations and Professional Resources

• Clinical insights and case pathways drawn from my work at sciatica.clinic: https://sciatica.clinic/
• Professional profile and educational engagements: https://www.linkedin.com/in/dralexjimenez/

Conclusion

Pain begins in the periphery, but relief arises when we address the entire pathway. By combining targeted topicals, precise chiropractic mechanics, carefully selected membrane stabilizers and SNRIs/TCAs, and systemic functional medicine, we produce safer, more effective, and durable outcomes. With Dr. Cardenas’s leadership, our multidisciplinary model ensures evidence-based, safety-first care for complex pain. With rehabilitation and patient education, we transform improvements into long-term function.

SEO tags: integrative pain management, chiropractic neuro-musculoskeletal care, internal medicine oversight, Dr Alex Jimenez, Dr Maria Guadalupe Cardenas, diclofenac gel, lidocaine patches, capsaicin Qutenza, TRPV1 desensitization, gabapentin membrane stabilizer, pregabalin dosing, duloxetine musculoskeletal pain, tricyclic antidepressants, burning mouth syndrome, benzodiazepine risks, muscle relaxants sciatica, low-dose naltrexone, opioid metabolism CYP450, buprenorphine chronic pain, methadone NMDA, opioid-induced constipation PAMORAs, naloxone education, sciatica clinic, El Paso Injury Medical Clinic, functional medicine pain, spinal segmental gating, descending inhibition norepinephrine, personal injury rehabilitation, dorsal root ganglion, nociceptor sensitization, prostaglandins, substance P, CGRP